The development of copper radiopharmaceuticals for imaging and therapy

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 413-429

  Shokeen, Monica ^a   Wadas, Thaddeus J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bifunctional chelator; Copper; Molecular imaging; Positron emission tomography; Radionuclide; Radiopharmaceutical

Indexed keywords

ANTIBODY; COORDINATION COMPOUND; COPPER 60; COPPER 61; COPPER 62; COPPER 64; COPPER 67; COPPER COMPLEX; COPPER DERIVATIVE; NANOPARTICLE; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIOISOTOPE DECAY; REVIEW;

COPPER RADIOISOTOPES; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80052014405     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799177     Document Type: Review

References (185)

1. Society of Nuclear Medicine http://interactive.snm.org/index.cfm? PageID=5571&RPID=969. Accessed December 25, 2010.
2. Welch, M. J.; Redvanly, C. S.; Editors: Handbook of Radiopharmaceuticals: Radiochemistry and Applications. Hoboken, NJ, John Wiley & Sons Inc., 2003.
3. Blower, P. J.; Lewis, J. S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol., 1996, 23, 957-980. (Pubitemid 27050682)
4. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. Copper in diseases and treatments, and copper-based anticancer strategies. Med. Res. Rev., 2009, 30, 708-749.
5. Crisponi, G.; Nurchi, V. M.; Fanni, D.; Gerosa, C.; Nemolato, S.; Faa, G. Copper-related diseases: From chemistry to molecular pathology. Coord. Chem. Rev., 2008, 254, 876-889.
6. Bertini, I.; Cavallaro, G.; McGreevy, K. S. Cellular copper management-a draft user's guide. Coord. Chem. Rev., 2007, 254, 506-524.
7. Boal, A. K.; Rosenzweig, A. C. Structural biology of copper trafficking. Chem. Rev., 2009, 109, 4760-4779.
8. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem. Soc. Rev., 2004, 33, 445-461. (Pubitemid 39461952)
9. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev., 2010, 110, 2858-2902.
10. Anderson, C. J.; Welch, M. J. Radiometal-labeled agents (nontechnetium) for diagnostic imaging. Chem. Rev., 1999, 99, 2219-2234.
11. Levason, W.; Spicer, M. D. The chemistry of copper and silver in their higher oxidation states. Coord. Chem. Rev., 1987, 76, 45-120.
12. Kaim, W., Rall, J. Copper-a "modern" bioelement. Angew. Chem. Int. Ed. Engl., 1996, 35, 43-60.
13. natZn at a medical cyclotron. Appl. Radiat. Isot., 2006, 64, 1563-1573. (Pubitemid 44649280)
14. McCarthy, D. W.; Bass, L. A.; Cutler, P. D.; Shefer, R. E.; Klinkowstein, R. E.; Herrero, P.; Lewis, J. S.; Cutler, C. S.; Anderson, C. J.; Welch, M. J. High purity production and potential applications of copper-60 and copper-61. Nucl. Med. Biol., 1999, 26, 351-358. (Pubitemid 29254019)
15. 61Cu-ATSM. Radiochim. Acta., 2004, 92, 209-214.
16. 64Cu. Nucl. Instrum. Methods Phys. Res., Sect. B. 2005, 240, 625-637. (Pubitemid 41562837)
17. 62Cu on a small cyclotron. Radiochim. Acta., 1992, 57, 1-5.
18. Williams, H. A.; Robinson, S.; Julyan, P.; Zweit, J.; Hastings, D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur. J. Nucl. Med. Mol. Imag., 2005, 32, 1473-1480. (Pubitemid 41746853)
19. Fujibayashi, Y.; Matsumoto, K.; Yonekura, Y.; Konishi, J.; Yokayama, A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J. Nucl. Med., 1989, 30, 1838-1842.
20. Zweit, J.; Gordall, R.; Cox, M.; Babich, J. W.; Petter, G. A.; Sharma, H. L.; Ott, R. J. Development of a high performance Zinc-61->Copper-62 generator for positron emission tomography. Eur. J. Nucl. Med., 1992, 14, 418-425.
21. 62Cu generator based on a cation exchanger and its fully remotecontrolled preparation for clinical use. Nucl. Med. Biol., 2006, 33, 821-827. (Pubitemid 44247729)
22. 64Cu and applications to molecular imaging by PET and PETIS as a biomedical tracer. J. Radioanal. Nucl. Chem., 2009, 280, 199-205.
23. 64Cu radioisotope production. J. Radioanal. Nucl. Chem., 2008, 277, 451-466.
24. 89Sr via (n, p) reactions induced by fast spectral neutrons. Radiochim. Acta., 2004, 92, 183-186.
25. 67Cu process. Appl. Radiat. Isot., 2003, 59, 343-351. (Pubitemid 37410268)
26. 64Zn. Appl. Radiat. Isot., 2006, 64, 1001-1005. (Pubitemid 44119180)
27. 64Cu reaction and dual ion-exchange column chromatography. Radiochim. Acta., 2007, 95, 75-80.
28. Novak-Hofer, I.; Schubiger, P. A. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imag., 2002, 29, 821-830.
29. 67Cu from irradiated zinc for use in antibody labelling: a comparison of methods. App. l Radiat. Isot., 1995, 46, 329-336.
30. 124I for radionuclide therapy and positron emission tomography. Radiochemistry, 2005, 47, 502-509. (Pubitemid 41407091)
31. 67Cu from proton irradiated Zn. Appl. Radiat. Isot., 1991, 42, 371-376.
32. 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother. Radiopharm., 2001, 16, 213-225. (Pubitemid 32641219)
33. Wun, T.; Kwon, D. S.; Tuscano, J. M. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma. Bio Drugs., 2001, 15, 151-162.
34. Zimmermann, K.; Gianollini, S.; Schubiger, P. A.; Novak-Hofer, I. A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F (ab') 2 fragments. Nucl. Med. Biol., 1999, 26, 943-950. (Pubitemid 30047165)
35. Frier, M. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer. Mini-Rev. Med. Chem., 2004, 4, 61-68. (Pubitemid 38842595)
36. 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl. Med. Biol., 2003, 30, 417-427. (Pubitemid 36589050)
37. 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-hodgkin's lymphoma: A pilot study. Anticancer Res., 1998, 18, 2779-2788. (Pubitemid 28388837)
38. 67Cu-2- iminothiolane-6-[p-(bromoacetamido) benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 1999, 5, 3330s-3336s. (Pubitemid 29493934)
39. Mirick, G. R.; O'Donnell, R. T.; DeNardo, S. J.; Shen, S.; Meares, C. F.; DeNardo, G. L. Transfer of copper from a chelated 67Cuantibody conjugate to ceruloplasmin in lymphoma patients. Nucl. Med. Biol., 1999, 26, 841-845. (Pubitemid 29509811)
40. 67Cu-2IT-Lym-1 for Non-Hodgkin's Lymphoma. J. Nucl. Med., 1999, 40, 2014-2020. (Pubitemid 30022015)
41. Table of Isotopes. ed 7, New York, John Wiley & Sons, 1978.
42. Aloj, L.; Morelli, G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr. Pharm. Des., 2004, 10, 3009-3031. (Pubitemid 39214008)
43. Vavere, A. L.; Lewis, J. S. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans., 2007, 4893-4902. (Pubitemid 350015414)
44. Hwang, D.-R.; Bergmann, S. R. Radiopharmaceuticals for studying the heart. Handb. Radiopharm., 2003, 529-555.
45. Keng, F. Y. J. Clinical applications of positron emission tomography in cardiology: a review. Ann. Acad. Med. Singapore, 2004, 33, 175-182. (Pubitemid 38684852)
46. Yetkin, F. Z.; Mendelsohn, D. Hypoxia imaging in brain tumors. Neuro. Clin. N. Am., 2002, 12, 537-552. (Pubitemid 36015490)
47. Lewis, J. S.; Dearling, J. L. J.; Sosabowski, J. K.; Zweit, J.; Carnochan, P.; Kelland, L. R.; Coley, H. M.; Blower, P. J. Copper bis (diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumors by PET. Eur. J. Nucl. Med., 2000, 27, 638-646. (Pubitemid 30408764)
48. 64Cu (DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance. Bioconjugate Chem., 2009, 20, 790-798.
49. 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. J. Nucl. Med., 2009, 50, 1332-1339.
50. Takahashi, N.; Fujibayashi, Y.; Yonekura, Y.; Welch, M. J.; Waki, A.; Tsuchida, T.; Sadato, N.; Sugimoto, K.; Nakano, A.; Lee, J. D.; Itoh, H. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann. Nucl. Med., 2001, 15, 293-296. (Pubitemid 32679229)
51. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur. J. Nucl. Med., 2001, 28, 99-103. (Pubitemid 32120812)
52. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med., 1997, 38, 1155-1160. (Pubitemid 27339632)
53. Holland, J. P.; Lewis, J. S.; Dehdashti, F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q. J. Nucl. Med. Mol. Imag., 2009, 53, 193-200.
54. 62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol. Pharm. Bull., 1993, 26, 146-149. (Pubitemid 23129188)
55. Dearling, J. L. J.; Lewis, J. S.; Welch, M. J.; McCarthy, D. W.; Blower, P. J. Redox-active complexes for imaging hypoxic tissues: structure-activity relationships in copper (II) bis (thiosemicarbazone) complexes. Chem. Commun., 1998, 22, 2531-2533.
56. Dearling, J. L. D.; Lewis, J. S.; Mullen, G. E. D.; Rae, M. T.; Zweit, J.; Blower, P. J. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur. J. Nucl. Med., 1998, 25, 788-792. (Pubitemid 28377043)
57. Dearling, J. L. J.; Lewis, J. S.; Mullen, G. E. D.; Welch, M. J.; Blower, P. J. Copper bis (thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J. Biol. Inorg. Chem., 2002, 7, 249-259. (Pubitemid 36056377)
58. Holland, J. P.; Barnard, P. J.; Collison, D.; Dilworth, J. R.; Edge, R.; Green, J. C.; Heslop, J. M.; McInnes, E. J. L.; Salzmann, C. G.; Thompson, A. L. Synthesis, X-ray crystallography, spectroelectrochemistry and computational studies on potential copper-based radiopharmaceuticals. Eur. J. Inorg. Chem., 2008, 3549-3560.
59. Holland, J. P.; Barnard, P. J.; Collison, D.; Dilworth, J. R.; Edge, R.; Green, J. C.; McInnes, E. J. L. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem.-Eur. J., 2008, 14, 5890-5907.
60. Holland, J. P.; Aigbirhio, F. I.; Betts, H. M.; Bonnitcha, P. D.; Burke, P.; Christlieb, M.; Churchill, G. C.; Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Green, J. C.; Peach, J. M.; Vasudevan, S. R.; Warren, J. E. Functionalized bis (thiosemicarbazonato) complexes of zinc and copper: synthetic platforms toward site-specific radiopharmaceuticals. Inorg. Chem., 2007, 46, 465-485.
61. Holland, J. P.; Giansiracusa, J. H.; Bell, S. G.; Wong, L.-L.; Dilworth, J. R. In vitro kinetic studies on the mechanism of oxygendependent cellular uptake of copper radiopharmaceuticals. Phys. Med. Biol., 2009, 54, 2103-2119.
62. Christlieb, M.; Struthers, H. S.; Bonnitcha, P. D.; Cowley, A. R.; Dilworth, J. R. The exocyclic functionalisation of bis (thiosemicarbazonate) complexes of zinc and copper: the synthesis of monomeric and dimeric species. Dalton Trans., 2007, 5043-5054. (Pubitemid 350017646)
63. Christlieb, M.; Dilworth, J. R. Ligands for molecular imaging: the synthesis of bis (thiosemicarbazone) ligands. Chemistry, 2006, 12, 6194-6206. (Pubitemid 44325276)
64. 64Cu labelling of functionalised bis (thiosemicarbazonato) complexes. Chem. Commun., 2007, 46, 4052-4054.
65. Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Heslop, J. M.; Ratcliffe, S. J. Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu (ATSM)-amino acid] and [Cu (ATSM)-octreotide] conjugates. Dalton Trans., 2007, 209-217. (Pubitemid 44937137)
66. Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; White, J. M. Copper complexes of thiosemicarbazone-pyridylhydrazine (THYNIC) hybrid ligands: A new versatile potential bifunctional chelator for copper radiopharmaceuticals. Inorg. Chem., 2006, 45, 496-498.
67. 64Cucomplexes for the positron emission tomography imaging of hypoxia. J. Med. Chem., 2008, 51, 2985-2991. (Pubitemid 351706026)
68. Alsop, L.; Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Peach, J. M.; Rider, J. T. Investigations into some aryl substituted bis (thiosemicarbazones) and their copper complexes. Inorg. Chim. Acta., 2005, 358, 2770-2780. (Pubitemid 40599771)
69. Pascu, S. I.; Waghorn, P. A.; Kennedy, B. W.; Arrowsmith, R. L.; Bayly, S. R.; Dilworth, J. R.; Christlieb, M.; Tyrrell, R. M.; Zhong, J.; Kowalczyk, R. M.; Collison, D.; Aley, P. K.; Churchill, G. C.; Aigbirhio, F. I. Fluorescent copper (II) bis (thiosemicarbazonates): synthesis, structures, electron paramagnetic resonance, radiolabeling, in vitro cytotoxicity and confocal fluorescence microscopy studies. Chem. Asian J., 2009, 5, 506-519.
70. Pascu, S. I.; Waghorn, P. A.; Conry, T. D.; Betts, H. M.; Dilworth, J. R.; Churchill, G. C.; Pokrovska, T.; Christlieb, M.; Aigbirhio, F. I.; Warren, J. E. Designing Zn (II) and Cu (II) derivatives as probes for in vitro fluorescence imaging. Dalton Trans., 2007, 4988-4997. (Pubitemid 350015422)
71. 64Cu-bis (thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J. Nucl. Med., 2008, 49, 1862-1868.
72. Yoshii, Y.; Furukawa, T.; Kiyono, Y.; Watanabe, R.; Waki, A.; Mori, T.; Yoshii, H.; Oh, M.; Asai, T.; Okazawa, H.; Welch, M. J.; Fujibayashi, Y. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl. Med. Biol., 2010, 37, 395-404.
73. Oh, M.; Tanaka, T.; Kobayashi, M.; Furukawa, T.; Mori, T.; Kudo, T.; Fujieda, S.; Fujibayashi, Y. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl. Med. Biol., 2009, 36, 419-426.
74. Aft Rebecca, L.; Lewis Jason, S.; Zhang, F.; Kim, J.; Welch Michael, J. Enhancing targeted radiotherapy by copper (II) diacetylbis (N4- methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res., 2003, 63, 5496-5504. (Pubitemid 37139869)
75. 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells. Eur. J. Nucl. Med. Mol. Imag., 2004, 37, 330-338.
76. 64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors. J. Nucl. Med., 2006, 47, 2034-2041. (Pubitemid 47544991)
77. Vavere Amy, L.; Lewis Jason, S. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl. Med. Biol., 2008, 35, 273-279.
78. Takahashi, N.; Fujibayashi, Y.; Yonekura, Y.; Welch, M. J.; Waki, A.; Tsuchida, T.; Nakamura, S.; Sadato, N.; Sugimoto, K.; Yamamoto, K.; Yokoyama, A.; Ishii, Y. Evaluation of copper-62 ATSM in patients with lung cancer as a hypoxic tissue tracer. J. Nucl. Med., 1998, 39, 53P.
79. 62Cu labeled diacetyl-bis (N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann. Nucl. Med., 2000, 14, 323-328.
80. Dehdashti, F.; Mintun Mark, A.; Lewis Jason, S.; Bradley, J.; Govindan, R.; Laforest, R.; Welch Michael, J.; Siegel Barry, A. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imag., 2003, 30, 844-850. (Pubitemid 36734203)
81. 60Cu-ATSM in cancer of the uterine cervix. Mol. Imag. Biol., 2007, 9, 278-283. (Pubitemid 47304777)
82. 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 2008, 49, 1177-1182. (Pubitemid 351948028)
83. 60Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone). J. Nucl. Med., 2008, 49, 201-205. (Pubitemid 351225657)
84. 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int. J. Rad. Oncol. Biol. Phys., 2003, 55, 1233-1238. (Pubitemid 36338289)
85. 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis. Colon Rectum, 2008, 51, 1641-1648.
86. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des., 2007, 13, 3-16. (Pubitemid 46085298)
87. Meares, C. F. Chelating agents for the binding of metal ions to antibodies. Nucl. Med. Biol., 1986, 13, 311-318. (Pubitemid 16006438)
88. Sun, X.; Anderson, C. J. Production and applications of copper-64 radiopharmaceuticals. Methods in Enzymol., 2004, 386, 237-261. (Pubitemid 38657596)
89. Woodin, K. S.; Heroux, K. J.; Boswell, C. A.; Wong, E. H.; Weisman, G. R.; Niu, W.; Tomellini, S. A.; Anderson, C. J.; Zakharov, L. N.; Rheingold, A. L. Kinetic inertness and electrochemical behavior of copper (II) tetraazamacrocyclic complexes: Possible implications for in vivo stability. Eu. J. Inorg. Chem., 2005, 23, 4829-4833. (Pubitemid 41771349)
90. Heroux, K. J.; Woodin, K. S.; Tranchemontagne, D. J.; Widger, P. C. B.; Southwick, E.; Wong, E. H.; Weisman, G. R.; Tomellini, S. A.; Wadas, T. J.; Anderson, C. J.; Kassel, S.; Golen, J. A.; Rheingold, A. L. The long and short of it: the influence of N-carboxyethyl versus N-carboxymethyl pendant arms on in vitro and in vivo behavior of copper complexes of cross-bridged tetraamine macrocycles. Dalton Trans., 2007, 2150-2162. (Pubitemid 46791134)
91. Hnatowich, D. J.; Layne, W. W.; Childs, R. L.; Lanteigne, D.; Davis, M. A. Radioactive labeling of antibody: A simple and efficient method. Science, 1983, 220, 613-615. (Pubitemid 13130145)
92. Parker, D. Tumor targeting with radiolabelled macrocycle-antibody conjugates. Chem. Soc. Rev., 1990, 19, 271-291.
93. Kukis, D. L.; Li, M.; Meares, C. F. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg. Chem., 1993, 32, 3981-3982.
94. 57Co. Nucl. Med. Biol., 1986, 13, 363-368. (Pubitemid 16006446)
95. Meares, C. F.; Wensel, T. G. Metal chelates as probes of biological systems. Acc. Chem. Res., 1984, 17, 202-209.
96. Yeh, S. M.; Sherman, D. G.; Meares, C. F. A new route to \"bifunctional\" chelating agents: conversion of amino acids to analogs of ethylenedinitrilotetraacetic acid. Anal. Biochem., 1979, 100, 152-159. (Pubitemid 10157645)
97. Moi, M. K.; Meares, C. F.; McCall, M. J.; Cole, W. C.; DeNardo, S. J. Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 1985, 148, 249-253. (Pubitemid 15031793)
98. Meares, C. F.; McCall, M. J.; Reardan, D. T.; Goodwin, D. A.; Diamanti, C. I.; McTigue, M. Conjugation of antibodies with bifunctional chelating agents: Isothicyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Chem., 1984, 142, 68-78.
99. Busch, D. H. The compleat coordination chemistry. One practitioner's perspective. Chem. Rev., 1993, 93, 847-860.
100. Riesen, A.; Zehnder, M.; Kaden, T. A. Cu-TETA crystal structure. Acta Crystallogr., 1988, C44, 1740-1742.
101. Riesen, A.; Zehnder, M.; Kaden, T. A. Cu-DOTA crystal structure. Helv. Chimica Acta, 1986, 69, 2067-2073.
102. 64Cu-labeled tetrameric RGD Peptide. J. Nucl. Med., 2005, 46, 1707-1718. (Pubitemid 46211595)
103. 86Y-DOTA-ReCCMSH (Arg11), a cyclized peptide analogue of alpha-MSH. J. Med. Chem., 2005, 48, 2985-2992. (Pubitemid 40548110)
104. 64Culabeled RGD peptide. Bioconjugate Chem., 2004, 15, 41-49. (Pubitemid 38165979)
105. 64Cu-Labeled RGD Peptide. Bioconjugate Chem., 2004, 15, 41-49. (Pubitemid 38165979)
106. Chen, X.; Sievers, E.; Hou, Y.; Park, R.; Tohme, M.; Bart, R.; Bremner, R.; Bading, J. R.; Conti, P. S. Integrin avb3-targeted imaging of lung cancer. Neoplasia, 2005, 7, 271-279.
107. Li, W. P.; Lewis, J. S.; Srinivasan, A.; Schmidt, M. A.; Anderson, C. J. Copper-64/61 and iodine-125-labeled DOTA-D-TYR1-octreotate: a new somatostatin analog for labeling with metals and halogens. J. Labld. Comp. Radiopharmaceut., 2001, 44 (suppl. 1), S948-S950.
108. Anderson, C. J.; Schwarz, S. W.; Connett, J. M.; Cutler, P. D.; Guo, L. W.; Germain, C. J.; Philpott, G. W.; Zinn, K. R.; Greiner, D. P.; Meares, C. F.. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F (ab') 2. J. Nucl. Med., 1995, 36, 850-858.
109. Anderson, C. J.; Sherman, E. L. C.; McCarthy, D. W.; Bass, L. A.; Jones, L. W.; Cristel, M. E.; Lanahan, M. V.; Shefer, R. E.; Klinkowstein, R. E.; Welch, M. J. Radiotherapy studies of Cu-64-Labeled TETA-octreotide in tumor-bearing rats. The J. Nucl. Med., 1996, 37, 128P.
110. Anderson, C. J.; Jones, L. A.; Bass, L. A.; Sherman, E. L. C.; McCarthy, D. W.; Cutler, P. D.; Lanahan, M. V.; Cristel, M. E.; Lewis, J. S.; Schwarz, S. W. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med., 1998, 39, 1944-1951. (Pubitemid 28518897)
111. Anderson, C. J.; Dehdashti, F.; Cutler, P. D.; Schwarz, S. W.; Laforest, R.; Bass, L. A.; Lewis, J. S.; McCarthy, D. W. Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42, 213-221. (Pubitemid 32150511)
112. Cutler, P. D.; Schwarz, S. W.; Anderson, C. J.; Connett, J. M.; Welch, M. J.; Philpott, G. W.; Siegel, B. A. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J. Nucl. Med., 1995, 36, 2363-2371.
113. DeNardo, S.; DeNardo, G.; Kukis, D.; Mausner, L.; Moody, D.; Meares, C. Pharmacology of Cu-67-TETA-Lym-1 antibody in patients with B cell lymphoma. Antib. Immunoconj. Radiopharmaceut., 1991, 4, 36.
114. 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J. Med. Chem., 1999, 42, 1341-1347. (Pubitemid 29200869)
115. 64Cu-BAT-2IT-1A3. Cancer Biother. Radiopharmaceut., 2001, 16, 483-494. (Pubitemid 34024436)
116. Wang, M.; Caruano, A. L.; Lewis, M. R.; Ballard, L.; Kelly, K.; Van der Waal, R. P.; Anderson, C. J. Subcellular fractionation of copper-64-TETA- octreotide in AR42J rat pancreatic tumor cells. Q. J. Nucl. Med., 2001, 45, S12.
117. Bass, L. A.; Wang, M.; Welch, M. J.; Anderson, C. J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjugate Chem., 2000, 11, 527-532. (Pubitemid 30597722)
118. Boswell, C. A.; Sun, X.; Niu, W.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med. Chem., 2004, 47, 1465-1474. (Pubitemid 38327472)
119. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42, 213-221. (Pubitemid 32150511)
120. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Del. Rev., 2008, 60, 1347-1370.
121. 68GalLabeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconj. Chem., 2009, 20, 1016-1025.
122. 2)]: a site-directed radiopharmaceutical for positronemission tomography imaging of T-47D human breast cancer tumors. Nucl. Med. Biol., 2009, 36, 171-181.
123. 2] targeting vector for positronemission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U S A., 2007, 104, 12462-12467. (Pubitemid 47206160)
124. 64) Cu-labeled RGD-bombesin heterodimer. J. Nucl. Med., 2009, 50, 1168-1177.
125. Ma, D.; Lu, F.; Overstreet, T.; Milenic, D. E.; Brechbiel, M. W. Novel chelating agents for potential clinical applications of copper. Nucl. Med. Biol., 2002, 29, 91-105. (Pubitemid 34088165)
126. Turner, J.; Koumenis, C.; Kute Timothy, E.; Planalp Roy, P.; Brechbiel Martin, W.; Beardsley, D.; Cody, B.; Brown Kevin, D.; Torti Frank, M.; Torti Suzy, V. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood, 2005, 106, 3191-3199. (Pubitemid 41565918)
127. Torti, S. V.; Ma, R.; Venditto, V. J.; Torti, F. M.; Planalp, R. P.; Brechbiel, M. W. Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents. Bioorg. Med. Chem., 2005, 13, 5961-5967. (Pubitemid 41399905)
128. Chong, H.-S.; Torti, S. V.; Ma, R.; Torti, F. M.; Brechbiel, M. W. Synthesis and potent antitumor activities of novel 1, 3, 5-cis, cistriaminocyclohexane N-pyridyl derivatives. J. Med. Chem., 2004, 47, 5230-5234. (Pubitemid 39314920)
129. Ye, N.; Park, G.; Przyborowska, A. M.; Sloan, P. E.; Clifford, T.; Bauer, C. B.; Broker, G. A.; Rogers, R. D.; Ma, R.; Torti, S. V.; Brechbiel, M. W.; Planalp, R. P. Nickel (II), copper (II) and zinc (II) binding properties and cytotoxicity of tripodal, hexadentate tris (ethylenediamine)-analogue chelators. Dalton Trans., 2004, 1304-1311.
130. Zhao, R.; Planalp, R. P.; Ma, R.; Greene, B. T.; Jones, B. T.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem. Pharmacol., 2004, 67, 1677-1688. (Pubitemid 38479846)
131. Chong, H.-s.; Torti, F. M.; Torti, S. V.; Brechbiel, M. W. Synthesis of 1, 3, 5-cis, cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents. J. Org. Chem., 2002, 67, 8072-8078. (Pubitemid 35331982)
132. Park, G.; Dadachova, E.; Przyborowska, A.; Lai, S.-j.; Ma, D.; Broker, G.; Rogers, R. D.; Planalp, R. P.; Brechbiel, M. W. Synthesis of novel 1, 3, 5-cis, cis-triaminocyclohexane ligand based Cu (II) complexes as potential radiopharmaceuticals and correlation of structure and serum stability. Polyhedron, 2001, 20, 3155-3163. (Pubitemid 33138914)
133. Ma, D.; Lu, F.; Overstreet, T.; Milenic, D. E.; Brechbiel, M. W. Novel chelating agents for potential clinic applications of copper. Nucl. Med. Biol., 2002, 29, 91-105. (Pubitemid 34088165)
134. Brady, E. D.; Chong, H.-S.; Milenic, D. E.; Brechbiel, M. W. Development of a spectroscopic assay for bifunctional ligandprotein conjugates based on copper. Nucl. Med. Biol., 2004, 31, 795-802. (Pubitemid 38887762)
135. Geue, R. J.; Hambley, T. W.; Harrowfield, J. M.; Sargeson, A. M.; Snow, M. R. Metal ion encapsulation: Cobalt cages derived from polyamines, formaldehyde, and nitromethane. J. Am. Chem. Soc., 1984, 106, 5478-5488.
136. Sargeson, A. M. The potential for the cage complexes in biology. Coord. Chem. Rev., 1996, 151, 89-114.
137. Grondahl, L.; Hammershoi, A.; Sargeson, A. M.; Thoem, V. J. Stability and kinetics of acid-and anion-assisted dissociation reactions of hexaamine macrobicyclic mercury (II) complexes. Inorg. Chem., 1997, 36, 5396-5403. (Pubitemid 127502682)
138. Di Bartolo, N. M.; Sargeson, A. M.; Donlevy, T. M.; Smith, S. V. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J. Chem. Soc., Dalton Trans., 2001, 2303-2309. (Pubitemid 35166719)
139. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptorexpressing prostate cancer. J. Nucl. Med., 52, 470-477.
140. Smith, S. V. Molecular imaging with copper-64. J. Inorg. Biochem., 2004, 98, 1874-1901. (Pubitemid 39456427)
141. 64Cu-SarAr immunoconjugates. Proc. Natl. Acad. Sci. U. S. A., 2007, 1-5.
142. Dearling, J. L. J.; Voss, S., D.; Dunning, P.; Snay, E.; Fahey, F.; Smith, S. V.; Huston, J. S.; Meares, C. F.; Treves, S. T.; Packard, A. B. Imaging cancer using PET-the effect of the bifunctional chelator on the biodistribution of a (64) Cu-labeled antibody. Nucl. Med. Biol., 38, 29-38.
143. Smith, S. V. Molecular imaging with copper-64. J. Inorg. Biochem., 2004, 98, 1874-1901. (Pubitemid 39456427)
144. Weisman, G. R.; Rogers, M. E.; Wong, E. H.; Jasinski, J. P.; Paight, E. S. Cross-bridged cyclam. Protonation and Li+ complexation in a diamond-lattice cleft. J. Am. Chem. Soc., 1990, 112, 8604-8605.
145. Weisman, G. R.; Wong, E. H.; Hill, D. C.; Rogers, M. E.; Reed, D. P.; Calabrese, J. C. Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands. J. Chem. Soc. Chem. Commun., 1996, (8), 947-948. (Pubitemid 126425147)
146. Sun, X.; Wuest, M.; Weisman, G. R.; Wong, E. H.; Reed, D. P.; Boswell, C. A.; Motekaitis, R.; Martell, A. E.; Welch, M. J.; Anderson, C. J. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J. Med. Chem., 2002, 45, 469-477. (Pubitemid 34073464)
147. Sprague, J. E.; Peng, Y.; Sun, X.; Weisman, G. R.; Wong, E. H.; Achilefu, S.; Anderson, C. J. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer Res., 2004, 10, 8674-8682. (Pubitemid 40053436)
148. Wadas, T. J.; Anderson, C. J. Radiolabeling of TETA-and CB-TE2A-conjugated peptides with copper-64. Nat. Prot., 2006, 1, 3062-3068.
149. Sprague, J. E.; Peng, Y.; Fiamengo, A. L.; Woodin, K. S.; Southwick, E. A.; Weisman, G. R.; Wong, E. H.; Golen, J. A.; Rheingold, A. L.; Anderson, C. J. Synthesis, characterization and in vivo studies of Cu (II)-64-labeled cross-bridged tetraazamacrocycleamide complexes as models of peptide conjugate imaging agents. J. Med. Chem., 2007, 50, 2527-2535. (Pubitemid 46799265)
150. Lewis, E. A.; Boyle, R. W.; Archibald, S. J. Ultrastable complexes for in vivo use: a bifunctional chelator incorporating a crossbridged macrocycle. Chem. Comm., 2004, 2212-2213. (Pubitemid 39472544)
151. 64Cu radiolabeling. Bioconj. Chem., 2008, 19, 1476-1484. (Pubitemid 352032349)
152. Stigers, D. J.; Ferdani, R.; Weisman, G. R.; Wong, E. H.; Anderson, C. J.; Golen, J. A.; Moore, C.; Rheingold, A. L. A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper (II) binding for radiopharmaceutical applications. Dalton Trans., 2011, 39, 1699-1701.
153. Veronese, F. M.; Mero, A. The impact of PEGylation on biological therapies. Bio Drugs, 2008, 22, 315-329.
154. 64Cu. J. Nucl. Med., 2009, 50, 790-797.
155. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J. Nucl. Med., 2004, 45, 1776-1783. (Pubitemid 47618490)
156. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24, 389-427. (Pubitemid 37056239)
157. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer, 1999, 83, 657-663. (Pubitemid 29508046)
158. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J. Nucl. Med., 2003, 44, 823-831. (Pubitemid 39655218)
159. 111In- DOTA-X-BBN (7-14) NH2 structural paradigm in a postate cancer model. Bioconj. Chem., 2008, 19, 1803-1812.
160. 68Ga-labeled bombesin (6-14) analog. J. Nucl. Med. 2005, 46, 691-699. (Pubitemid 41721868)
161. Dimitrakopoulou-Strauss, A.; Hohenberger, P.; Eisenhut, M.; Maecke, H. R.; Haberkorn, U.; Strauss, L. Receptor expression in patients with gastrointestinal stromal tumors (GIST) using a Ga-68-labeled Bombesin analogue. J. Nucl. Med., 2006, 47, 102P.
162. 4)-Bombesin (1-14). Bioconjug. Chem. 2007, 18, 724-730. (Pubitemid 47010791)
163. 64Cu-labeling, and bioconjugation of a new bis (2-pyridylmethyl) derivative of 1, 4, 7-Triazacyclononane. Bioconjug. Chem. 2008, 19, 719-730. (Pubitemid 351436371)
164. 64Cu-labeled bombesin analog. Bioconjug. Chem., 2003, 14, 756-763. (Pubitemid 36875435)
165. Parry, J. J.; Andrews, R.; Rogers, B. E. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrinreleasing peptide receptor. Breast Cancer Res. Treat., 2007, 101, 175-183. (Pubitemid 46115423)
166. 64Cu-labeled DOTA-linker-bombesin (7-14) analogues containing different amino acid linker moieties. Bioconjug. Chem., 2007, 18, 1110-1117. (Pubitemid 47122631)
167. 3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med., 2004, 45, 1390-1397. (Pubitemid 47618540)
168. Abd-Elgaliel, W. R.; Gallazzi, F.; Garrison, J. C.; Rold, T. L.; Sieckman, G. L.; Figueroa, S. D.; Hoffman, T. J.; Lever, S. Z. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug. Chem., 2008, 19, 2040-2048.
169. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med., 2007, 48, 1327-1337. (Pubitemid 47242799)
170. 64Cu-labeled bombesin analogue. Bioconjug. Chem., 2003, 14, 756-763. (Pubitemid 36875435)
171. Parry, J. J.; Andrews, R.; Rogers Buck, E. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res. Treat., 2007, 101, 175-183. (Pubitemid 46115423)
172. Schottelius, M.; Wester, H.-J. Molecular imaging targeting peptide receptors. Methods, 2009, 48, 161-177.
173. Anderson, C. J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother. Radiopharm., 2009, 24, 379-393.
174. Shokeen, M.; Anderson, C. J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res., 2009, 42, 832-841.
175. Reubi, J. C.; Waser, B.; Schaer, J.-C.; Laissue, J. A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med., 2001, 28, 836-846. (Pubitemid 32662546)
176. de Herder, W. W.; Lamberts, S. W. J. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine, 2003, 20, 285-290. (Pubitemid 36571031)
177. Li, W., P.; Meyer, L. M.; Anderson C., J. Radiopharmaceuticals for positron emission tomography imaging of somatostatin receptor positive tumors. Top. Curr. Chem., 2005, 252, 179-192. (Pubitemid 44420849)
178. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Fuger, B.; Li, S. R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Burggasser, G.; Andreae, F.; Kurtaran, A.; Dudczak, R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr. Pharm. Des., 2002, 8, 1781-1807.
179. 111In-pentetreotide scintigraphy. J. Nucl. Med., 2002, 43, 889-895. (Pubitemid 34747811)
180. Dehdashti, F.; Anderson, C. J.; Trask, D. D.; Bass, L. A.; Schwarz, S. W.; Cutler, P. D.; McCarthy, D. W.; Lanahan, M. V. Initial results with PET imaging using Cu-64-labeled TETA-octreotide in patients with carcinoid tumor. J. Nucl. Med., 1997, 38, 103P.
181. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J. Med. Chem., 1999, 42, 1341-1347. (Pubitemid 29200869)
182. Eiblmaier, M.; Andrews, R.; Laforest, R.; Rogers, B. E.; Anderson, C. J. Nuclear uptake and dosimetry of 64Cu-labeled chelatorsomatostatin conjugates in an SSTr2-transfected human tumor cell line. J. Nucl. Med., 2007, 48, 1390-1396. (Pubitemid 47242805)
183. Edwards, W. B.; Xu, B.; Akers, W.; Cheney Philip, P.; Liang, K.; Rogers Buck, E.; Anderson Carolyn, J.; Achilefu, S. Agonistantagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug. Chem., 2008, 19, 192-200. (Pubitemid 351213851)
184. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H. R.; Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16436-16441. (Pubitemid 44715214)
185. Wadas, T. J.; Eiblmaier, M.; Zheleznyak, A.; Sherman, C. D.; Ferdani, R.; Liang, K.; Achilefu, S.; Anderson, C. J. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J. Nucl. Med., 2008, 49, 1819-1827.